A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM
Recruiting now Phase 1/2 NCT06845202
Run by Alnylam Pharmaceuticals · for 18 to 75 · All sexes · accepts healthy volunteers
What this study is about
The purpose of this study is to: * evaluate the safety and tolerability of single ascending doses of ALN-4324 in healthy volunteers and to characterize the single-dose PK of ALN-4324 * evaluate the efficacy, safety, tolerability, and pharmacodynamics (PD) of multiple doses of ALN-4324 in adult overweight to obese patients with T2DM
Who can join (things the study team will check)
✅ You may be able to join if…
- Has a body mass index (BMI) of ≥27 kg/m\^2 and <40 kg/m\^2 Part B:
- Is an adult patient with a confirmed diagnosis of T2DM
- Has a hemoglobin A1c (HbA1c) ≥7% to <10.5%
- Has a BMI of ≥25 kg/m\^2 and <45 kg/m\^2
- Is on a stable dose of either metformin or metformin and a sodium-glucose cotransporter 2 inhibitor (SGLT2i)
🚫 You may not be able to join if…
- Has known human immunodeficiency virus (HIV) infection; or known current or chronic hepatitis C virus or hepatitis B virus infection Part B:
- Receiving therapies for chronic weight management or antidiabetic medications other than metformin and SGLT2i Note: other protocol defined inclusion/exclusion criteria apply
Where this trial is running
- Clinical Trial Site, Montclair, California, United States
- Clinical Trial Site, Washington D.C., District of Columbia, United States
- Clinical Trial Site, Miami, Florida, United States
- Clinical Trial Site, Marlton, New Jersey, United States
- Clinical Trial Site, Monroe, North Carolina, United States
- Clinical Trial Site, Dallas, Texas, United States
- Clinical Trial Site, Dallas, Texas, United States
- Clinical Trial Site, Buenos Aires, Argentina
- Clinical Trial Site, Buenos Aires, Argentina
- Clinical Trial Site, Buenos Aires, Argentina
- Clinical Trial Site, San Miguel de Tucumán, Argentina
- Clinical Trial Site, Concord, Canada
+ 10 more sites.
Who to contact
Alnylam Clinical Trial Information Line · 1-877-ALNYLAM · clinicaltrials@alnylam.com
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT06845202.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.